FDA Approved: FAMOTIDINE — Supplemental Application (Akorn)

View source ↗

Summary

FDA approved a supplemental application for famotidine from Akorn (ANDA 201995). This approval confirms continued availability of this generic H2 blocker.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duodenal Ulcer
• Gastric Ulcer
• Gastroesophageal Reflux Disease
• Peptic Ulcer Disease

Drugs mentioned

• Famotidine (famotidine)

Snippet

SUPPL AP for FAMOTIDINE (FAMOTIDINE)